Literature DB >> 16574867

A critical role for the innate immune signaling molecule IRAK-4 in T cell activation.

Nobutaka Suzuki1, Shinobu Suzuki, Douglas G Millar, Midori Unno, Hiromitsu Hara, Thomas Calzascia, Sho Yamasaki, Tadashi Yokosuka, Nien-Jung Chen, Alisha R Elford, Jun-Ichiro Suzuki, Arata Takeuchi, Christine Mirtsos, Denis Bouchard, Pamela S Ohashi, Wen-Chen Yeh, Takashi Saito.   

Abstract

IRAK-4 is a protein kinase that is pivotal in mediating signals for innate immune responses. Here, we report that IRAK-4 signaling is also essential for eliciting adaptive immune responses. Thus, in the absence of IRAK-4, in vivo T cell responses were significantly impaired. Upon T cell receptor stimulation, IRAK-4 is recruited to T cell lipid rafts, where it induces downstream signals, including protein kinase C activation through the association with Zap70. This signaling pathway was found to be required for optimal activation of nuclear factor kappaB. Our findings suggest that T cells use this critical regulator of innate immunity for the development of acquired immunity, suggesting that IRAK-4 may be involved in direct signal cross talk between the two systems.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16574867     DOI: 10.1126/science.1124256

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  34 in total

Review 1.  Regulations and roles of the interleukin-1 receptor associated kinases (IRAKs) in innate and adaptive immunity.

Authors:  Lu Gan; Liwu Li
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

2.  Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth.

Authors:  Qifa Xie; Lu Gan; Jianxia Wang; Ingred Wilson; Liwu Li
Journal:  Mol Immunol       Date:  2007-05-02       Impact factor: 4.407

Review 3.  The involvement of the interleukin-1 receptor-associated kinases (IRAKs) in cellular signaling networks controlling inflammation.

Authors:  Lorna Ringwood; Liwu Li
Journal:  Cytokine       Date:  2008-01-30       Impact factor: 3.861

4.  Genome-wide analysis of polymorphisms associated with cytokine responses in smallpox vaccine recipients.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; V Shane Pankratz; Iana H Haralambieva; Robert A Vierkant; Gregory A Poland
Journal:  Hum Genet       Date:  2012-05-19       Impact factor: 4.132

5.  Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.

Authors:  Zhaoyang Li; Kenisha Younger; Ronald Gartenhaus; Ann Mary Joseph; Fang Hu; Maria R Baer; Patrick Brown; Eduardo Davila
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

Review 6.  Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors.

Authors:  Sean R Christensen; Mark J Shlomchik
Journal:  Semin Immunol       Date:  2007-02-02       Impact factor: 11.130

7.  Impaired T-cell receptor activation in IL-1 receptor-associated kinase-4-deficient patients.

Authors:  Douglas R McDonald; Frederick Goldman; Oscar D Gomez-Duarte; Andrew C Issekutz; Dinakantha S Kumararatne; Rainer Doffinger; Raif S Geha
Journal:  J Allergy Clin Immunol       Date:  2010-08       Impact factor: 10.793

8.  Chemical proteomic map of dimethyl fumarate-sensitive cysteines in primary human T cells.

Authors:  Megan M Blewett; Jiji Xie; Balyn W Zaro; Keriann M Backus; Amnon Altman; John R Teijaro; Benjamin F Cravatt
Journal:  Sci Signal       Date:  2016-09-13       Impact factor: 8.192

9.  The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease.

Authors:  Masayuki Fukata; Keith Breglio; Anli Chen; Arunan S Vamadevan; Tyralee Goo; David Hsu; Daisy Conduah; Ruliang Xu; Maria T Abreu
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

10.  Tube Is an IRAK-4 homolog in a Toll pathway adapted for development and immunity.

Authors:  Par Towb; Huaiyu Sun; Steven A Wasserman
Journal:  J Innate Immun       Date:  2009       Impact factor: 7.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.